Geron Corp. (GERN)
1.52
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
1.52
0.00 (0.00%)
After-Hours: 20:00
Geron EPS Diluted (Quarterly) : -0.0249 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0249 |
| March 31, 2026 | -0.0054 |
| December 31, 2025 | -0.0467 |
| September 30, 2025 | -0.0276 |
| June 30, 2025 | -0.0246 |
| March 31, 2025 | -0.0298 |
| December 31, 2024 | -0.0382 |
| September 30, 2024 | -0.0399 |
| June 30, 2024 | -0.103 |
| March 31, 2024 | -0.0918 |
| December 31, 2023 | -0.0874 |
| September 30, 2023 | -0.0773 |
| June 30, 2023 | -0.09 |
| March 31, 2023 | -0.07 |
| December 31, 2022 | -0.1045 |
| September 30, 2022 | -0.1013 |
| June 30, 2022 | -0.0696 |
| March 31, 2022 | -0.0906 |
| December 31, 2021 | -0.0968 |
| September 30, 2021 | -0.0812 |
| June 30, 2021 | -0.0904 |
| March 31, 2021 | -0.086 |
| December 31, 2020 | -0.0746 |
| September 30, 2020 | -0.0616 |
| June 30, 2020 | -0.0641 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0817 |
| December 31, 2019 | -0.1465 |
| September 30, 2019 | -0.0803 |
| June 30, 2019 | -0.0763 |
| March 31, 2019 | -0.054 |
| December 31, 2018 | -0.0392 |
| September 30, 2018 | -0.0304 |
| June 30, 2018 | -0.0397 |
| March 31, 2018 | -0.0448 |
| December 31, 2017 | -0.0466 |
| September 30, 2017 | -0.0433 |
| June 30, 2017 | -0.0402 |
| March 31, 2017 | -0.0451 |
| December 31, 2016 | -0.05 |
| September 30, 2016 | -0.02 |
| June 30, 2016 | -0.05 |
| March 31, 2016 | -0.06 |
| December 31, 2015 | -0.05 |
| September 30, 2015 | 0.17 |
| June 30, 2015 | -0.06 |
| March 31, 2015 | -0.06 |
| December 31, 2014 | -0.06 |
| September 30, 2014 | -0.06 |
| June 30, 2014 | -0.06 |
| March 31, 2014 | -0.06 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Precigen, Inc. | 0.0485 |
| Editas Medicine, Inc. | -0.1528 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -16.68M |
| Revenue (Quarterly) | 57.48M |
| Total Expenses (Quarterly) | 74.16M |
| Enterprise Value | 925.59M |
| Gross Profit Margin (Quarterly) | 94.94% |
| Profit Margin (Quarterly) | -29.02% |
| Earnings Yield | -6.88% |
| Normalized Earnings Yield | -5.743 |